StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
044960.KQ$3200.00-4.62%
Fair $3200.00+0.0%

044960.KQ

Eagle Veterinary Technology Co.,Ltd

Unknown / UnknownKOSDAQ

$3200.00

-155.00 (-4.62%)

Fairly Valued+0.0%Fair Value $3200.00Fund rank 27/100 · Data gapFallback financials|
SA 43/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $1.5B · quality 47.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 044960.KQLocal privado en este navegador · Eagle Veterinary Technology Co.,Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$39.3B

P/E

10.0x

↑

EV/EBITDA

6.8x

↓

ROE

7.6%

↑

Gross Margin

34.1%

↑

Debt/Equity

0.13

↓
52-Week Range$3200
$3170$4970

TradingView lightweight chart

044960.KQ price, volumen y niveles de valoración

Último $3,200Periodo +4.7%
Fair value: $3,200

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-0.2%

FCF CAGR

—

FCF margin

9.0%

FCF / Net income

0.99x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $43.32B · net income $3.95B · FCF $3.90B

2022-FY → 2025-FY

Gross margin

34.1%+0.1% pts

Operating margin

10.1%+1.9% pts

Net margin

9.1%+3.0% pts

FCF margin

9.0%+10.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$43.32B$43.32B$41.72B$42.79B$43.54B
Net Income$3.95B$3.95B$3.71B$2.98B$2.64B
EBITDA$6.07B$6.07B$6.14B$5.01B$4.91B
EPS321.44321.44301.86242.44215.35
Gross Margin34.1%34.1%33.6%34.0%34.0%
Operating Margin10.1%10.1%8.6%7.8%8.2%
Net Margin9.1%9.1%8.9%7.0%6.1%
Balance Sheet
Debt/Equity0.130.130.140.170.16
Cash Flow
Free Cash Flow$3.90B$3.90B$1.50B$202.0M$-747.8M
Returns
ROE7.6%7.6%7.6%6.6%6.2%
Valuation
P/E9.969.9615.9321.8226.33
EV/EBITDA6.806.8010.2913.9615.25
P/B0.760.761.221.431.62
Growth & Yield
Revenue Growth3.9%3.9%-2.5%-1.7%—
EPS Growth6.5%6.5%24.5%12.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-4.0%

fácil

EPS terminal req.

$283.95

Spread vs growth

10.5%

5Y implied EPS CAGR

1.3%

fácil

EPS terminal req.

$343.58

Spread vs growth

5.1%

10Y implied EPS CAGR

5.6%

razonable

EPS terminal req.

$553.33

Spread vs growth

0.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -28.4%

Total return

-28.4%

Start / end P/E

14.8x → 10.0x

EPS bridge

301.86 → 321.44

Residual

-2.1%

EPS growth+6.5%
Multiple rerating-32.8%
Dividend+0.0%
Residual / FX / buybacks / cross-term-2.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.